Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer

A unique approach for cancer treatment including radioactive sources named Alpha DaRT sources: Ra - 224 coated onto stainless steel tubes inserted into the tumor for the treatment of Locally Advanced Pancreatic Cancer .

Trial Details

NCT ID
NCT06755359
Phase
NA
Sponsor
Alpha Tau Medical LTD.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Locations (sample)
  • Bordeaux, France|44.84124,-0.58046
  • Bordeaux, France|44.84124,-0.58046
  • Clermont-Ferrand, France|45.77969,3.08682
  • Dijon, France|47.31344,5.01391
  • Dijon, France|47.31344,5.01391

Key Eligibility Criteria

  • Histologically and/or cytologically proven locally advanced pancreatic adenocarcinoma
  • Target lesion is technically amenable for Alpha DaRT sources implantation.
  • Measurable lesion per RECIST (version 1.1) criteria
  • Stable disease or tumor response per RECIST (version 1.1) criteria compared to before initiation of mFOLFIRINOX

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →